Preclinical studies of SPECT and PET tracers for NET

Area of Science:

• Nuclear medicine
• Oncology
• Radiopharmaceutical science

Background:

• Radiolabeled somatostatin analogues are standard for diagnosing neuroendocrine tumors (NETs).
• These agents target somatostatin-receptor subtypes expressed on NET cell membranes.
• Tumor origin heterogeneity can lead to low or absent receptor expression, limiting diagnostic performance.

Purpose of the Study:

• To review recent advancements in radiolabeled peptide analogues for NET detection.
• To discuss the in vitro and in vivo characterization of these novel agents.
• To address the limitations of current somatostatin analogue-based imaging in specific NET subtypes.

Main Methods:

• Literature review of recent developments in radiolabeled peptide analogues.
• Analysis of in vitro studies characterizing receptor binding and specificity.
• Evaluation of in vivo studies assessing tumor uptake and diagnostic accuracy.

Main Results:

• Recent developments include novel peptide analogues with improved receptor affinity and targeting profiles.
• In vitro data show varying specificities for different somatostatin receptor subtypes.
• In vivo studies demonstrate potential for enhanced detection in certain NETs, but challenges remain for heterogeneous tumors.

Conclusions:

• Novel radiolabeled peptide analogues show promise for improving NET detection beyond current somatostatin analogues.
• Further research and characterization are needed to overcome limitations in heterogeneous NETs.
• Personalized imaging strategies may be required based on individual tumor receptor expression.